RxDoctor Payments DataLook up a doctor →

William Walsh, MD

Hematology & Oncology · Worcester, MANPI 1073597274

Payments from drug & device makers

$1,557,878in general payments, 2019–2025

Across 431 payments — averaging $3614.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.2M
  • GSK$251K
  • AstraZeneca$48K
  • AbbVie$20K
  • Regeneron$18K
  • Viiv Healthcare Company$1K
  • plus $2K from 12 others
$54in research payments, 2019–2025

Across 1 payment — averaging $54.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$54

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,557,878 in reported general payments places this provider in the 85th percentile of 374 hematology & oncology providers in Massachusetts.

See all hematology & oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$54,527
Medicare patients
192
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →